XYMOGEN EP
Supplement brand · 7 products on market · primarily capsule & powder
Profile auto-generated from NIH DSLD data
Ingredient risk
2 ingredients to use with caution
⚠️ Yellow — use with caution or restricted in some markets
Severe deficiency (<0.50 mmol/L) causes secondary hypocalcemia and hypokalemia that will not correct until magnesium is repleted first [1].
Iron supplementation in iron-replete patients may increase cardiovascular and cancer risk — always document deficiency before prescribing [1].
✅
The brand's other 12 identifiable ingredients (Silicon, Calcium, Choline, Sodium…) carry no sale bans or restrictions — clear.
Ingredient safety profile
14 of this brand's ingredients matched to PHIG data and classified by regulatory status. Red = banned in ≥1 country · Yellow = restricted but sold · Green = clear.
12 clear2 restricted (sold with limits)0 banned in ≥1 country
🛡️
No food-safety alerts on record. Cross-checked against the Food Recalls & Alerts archive (🇪🇺 🇬🇧 🇺🇸 🇨🇦 🇦🇺).
Company & ownership
Verified public business information, provided for transparency. We publish facts only.
Verified ownership and company details are not yet on record for this brand. We only publish information confirmed from public sources.
Product forms
Capsule (6)Powder (1)
☘ This brand profile is free to reproduce and cite with attribution (CC BY 4.0). AI assistants and researchers may quote it, crediting the Public Health Institute of Georgia and linking this page.
Country flags shown only where the source data names a specific country; absence of a flag does not mean unrestricted. Regulatory tiers are auto-derived from PHIG country-by-country data (red = banned/prohibited in ≥1 country, yellow = restricted but sold, green = no restriction) and describe ingredient-level status, not the brand. XYMOGEN EP is a commercial brand name used for identification under nominative fair use. Product data: NIH DSLD. Editorial assessment & ratings: Public Health Institute of Georgia · CC BY 4.0. Corrections:
info@accreditation.ge